[Event Report] The First Sub-committee on AMR of the Nikkei Asia Africa Conference on Communicable Diseases – Asia Africa Medical Innovation Consortium (AMIC) (January 22, 2020)
date : 2/11/2020
Tags: AMR
Nikkei Inc. and AMR Alliance Japan (Secretariat: Health and Global Policy Institute (HGPI)) jointly held the First Sub-committee on AMR of the Nikkei Asia Africa Conference on Communicable Diseases – Asia Africa Medical Innovation Consortium (AMIC).
At this first sub-committee, participants from academia, the Government, industry and civil society discussed potential policy options to ensure sustainable research and development (R&D) for antimicrobials.
Participants agreed to continue to discuss the state of the antimicrobial market in working groups toward the eventual formulation of a concrete proposal on ways to incentivize antimicrobial R&D in the future.
■Overview
Date and time: Wednesday, January 22, 2020
Organizer: AMR Alliance Japan (Secretariat: HGPI)
■Program
The role of the AMR sub-committee
Mitsuru Miyata (Adviser, Medical and Healthcare Division, Nikkei Business Publications, Inc.)
Shigeru Omi (President, Japan Community Health care Organization (JCHO) / Regional Director Emeritus, Regional Office for the Western Pacific (WPRO), World Health Organization (WHO))
AMR Alliance Japan
Ryoji Noritake (CEO, Board Member, Health and Global Policy Institute (AMR Alliance Japan Secretariat))
Kazuhiro Tateda (President, The Japanese Association for Infectious Diseases / President, The Japanese Society for Clinical Microbiology / Professor, Department of Microbiology and Infectious Diseases, Toho University)
Discussion —Policy options to revitalize the antimicrobial industry
From the perspective of the Cabinet Secretariat:
Hiroyuki Noda (Councilor, Coordination Office of Measures on Emerging Infectious Diseases, Office of Pandemic Influenza and New Infectious Diseases Preparedness and Response, Cabinet Secretariat)
From the perspective of the Ministry of Health, Labour and Welfare:
Manami Yanagawa (Chief, Tuberculosis and Infectious Diseases Control Division, Ministry of Health, Labour and Welfare (MHLW))
From the perspective of the pharmaceutical industry
Takeo Morooka (Executive Officer, Head of Health Policy and Corporate Support, MSD K.K.) Takuko Sawada (Executive Vice President, Shionogi & Co., Ltd.)
Chairs:
Shigeru Omi (President, Japan Community Health care Organization (JCHO) / Regional Director Emeritus, Regional Office for the Western Pacific (WPRO), World Health Organization (WHO))
Kazuhiro Tateda (President, The Japanese Association for Infectious Diseases / President, The Japanese Society for Clinical Microbiology / Professor, Department of Microbiology and Infectious Diseases, Toho University)
Facilitator:
Ryoji Noritake (CEO, Board Member, Health and Global Policy Institute (AMR Alliance Japan Secretariat))
Top Research & Recommendations Posts
- [Policy Recommendations] Kidney Disease Control Promotion Project 2023 “Establishing Kidney Disease Control Measures with Patient, Citizen, and Community Engagement and Collaboration” Policy Recommendations, a Collection of Good Practices of Chronic Kidney Disease (CKD) and Control Measures in Local Governments (February 14, 2024)
- [Announcement] A Significant Step Towards the Building a Green Healthcare System: Support for the Formal Expression of Interest by the Japanese Government Delegation to the ATACH at the Executive Board Meeting of the WHO (February 16, 2024)
- [Research Report] Survey of Japanese Physicians Regarding Climate Change and Health (December 3, 2023)
- [Research Paper] “Rethinking Japan’s Health System Sustainability Under the Planetary Health Framework” Published in Health Systems & Reform (November 21, 2023)
- [Research Report] The Public Opinion Survey on Child-Rearing in Modern Japan (Final Report) (March 4, 2022)
- [Research Report] 2019 Survey on Healthcare in Japan
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Announcement] HGPI Planetary Health Policy Team Joins Call for Global Fossil Fuel Non-proliferation Treaty (October 18, 2022)
- [Announcement] HGPI Joins Call for “Global Health and Medical Community Unite To Demand End Fossil Fuel Dependency at COP28” (November 1, 2023)
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
Featured Posts
-
2024-03-04
[Event Report] Non-partisan Diet Member Briefing – 30-minute Health Policy Update: “Issues Surrounding and Necessary Measures Against Obesity Disease” (February 2, 2024)
-
2024-03-05
[HGPI Policy Column] (No.41) – From the Mental Health Project Team – Mental Health Policy in Japan – History and Future Policy Topics (Part 1 of HGPI Activities for Mental Health and Domestic Policy History)
-
2024-03-18
[Registration Open] International Symposium “Promotion of Menopausal Women’s Health as a Social Issue to be Considered by Industry, Government, Academia and the Private Sector” (April 9, 2024)
-
2024-03-22
[Registration Open] (Hybrid Format) The Project for Considering the Future of Precision Medicine with Industry, Government, Academia, and Civil Society – The Global Expert Meeting: Toward Equitable Patient Access to Genomic Cancer Medicine (April 4, 2024)
-
2024-03-26
[Policy Recommendations] Dementia Prevention Initiatives for Achieving a Dementia-Friendly and Inclusive Society (March 26, 2024)